QUANTUM LEAP HEALTHCARE COLLABORATIVE
Programs
I-Spy Trials for Breast Cancer Treatment
I-SPY TRIALS: QUANTUM LEAP SPONSORS THE I-SPY TRIALS (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS). I-SPY HAS BEEN RE-ENGINEERING THE APPROACH TO CLINICAL TRIALS, WITH A GOAL OF GETTING THE RIGHT DRUG TO THE RIGHT PATIENT AT THE TIME WHEN THEY WILL BENEFIT MOST, AND TO ACHIEVE THIS FASTER THAN POSSIBLE IN PREVIOUS TRIAL MODELS. ADDITIONALLY, I-SPY AIMS TO SIGNIFICANTLY REDUCE THE OVERALL COST, TIME, AND NUMBER OF PATIENTS REQUIRED TO BRING NEW DRUGS TO MARKET. THE I-SPY TRIAL PROGRAM INTEGRATES AND LINKS PHASE I (I-SPY PHASE 1), PHASE II (I-SPY 2), AND FUTURE PHASES TO BUILD A PIPELINE OF NOVEL AGENTS AND ACCELERATE THE PROCESS OF IDENTIFYING THE SUBSET OF HIGH-RISK BREAST CANCER PATIENTS THAT WILL BENEFIT FROM THESE NEW AGENTS, AND GET THESE DRUG INTO THE CLINIC IN A TIMELY MANNER.GeographiesNot indicatedDatesJan 1, 2022 – Dec 31, 2022Source990No causes providedNo populations provided–$22.8MI-Spy COVID Trial for Critical Illness
DURING FISCAL YEAR 2020, THE I-SPY COVID TRIAL AN ADAPTIVE PLATFORM TRIAL, WAS DESIGNED TO RAPIDLY SCREEN AND CONFIRM HIGH IMPACT TREATMENTS TO REDUCE MORTALITY AND TIME ON VENTILATORS. THIS WORK IS INDEPENDENT AND EQUALLY AS IMPORTANT AS VACCINE EFFORTS. I-SPY COVID TRIAL FOCUSES ON THOSE PATIENTS WHOSE REACTIONS TO THE VIRUS MAKE THEM CRITICALLY ILL AND, IN MANY CASES, RESULTS IN DEATH. THE PRIMARY FOCUS OF THE TRIAL WAS TO IDENTIFY PROMISING DRUGS THAT EITHER NEUTRALIZE THE VIRUS, HELP HEAL THE LUNG DAMAGE FROM THE VIRUS (CAUSED BY ADULT RESPIRATORY DISTRESS SYNDROME OR (ARDS) OR TO CHANGE THE IMMUNE SYSTEM REACTION WHICH RESULTS IN ILLNESS (FOR YOUNGER PEOPLE, THIS IS ESPECIALLY IMPORTANT). THE TRIAL OPENED JUNE 2020 AND WILL CONTINUE TO RUN UNTIL A DRUG OR COMBINATIONS OF DRUGS, IS FOUND THAT PREVENTS THE NECESSITY FOR VENTILATION TREATMENT AND ELIMINATES DEATH FROM THE DISEASE.GeographiesNot indicatedDatesJan 1, 2022 – Dec 31, 2022Source990No causes providedNo populations provided–$20.1MBreast Cancer Trials Initiative
BREAST CANCER TRIALS (BCT) - LAUNCHED IN 2008, FOLLOWING A SUCCESSFUL UCSF-NCI SPONSORED RESEARCH PILOT, ITS MISSION IS TO MAKE PATIENT CONSIDERATION OF TRIALS THE NORM VS. THE EXCEPTION. WE BELIEVE THAT ALL PATIENTS SHOULD HAVE ACCESS TO THE LATEST MEDICAL KNOWLEDGE ABOUT BREAST CANCER TREATMENT AS WELL AS THE OPPORTUNITY TO ADVANCE BREAST CANCER RESEARCH. BCT LISTS OVER 600 STUDIES FOR PEOPLE WITH NEWLY DIAGNOSED BREAST CANCER, METASTATIC DISEASE, OR POST-TREATMENT SURVIVORS. IT INCLUDES INNOVATIVE TRIALS OF TARGETED AND IMMUNOTHERAPIES AS WELL AS OBSERVATIONAL STUDIES LOOKING AT QUALITY OF LIFE, GENETIC MUTATIONS, AND BREAST CANCER SURVIVORSHIP, ACCOMPANIED BY EASY-TO-READ TRIAL SUMMARIES.GeographiesNot indicatedDatesJan 1, 2022 – Dec 31, 2022Source990No causes providedNo populations provided–$1.2M
Copyright 2026. All rights reserved to Chario Inc. (d.b.a. Impala)